StockGuide AI
Track Stocks
EN RU ES DE
Merck

Merck

Price: 120.78

Company and Business Model

Merck & Co., Inc. is a global healthcare company that develops and manufactures pharmaceuticals, vaccines, biologics, and animal health products. Its core products include treatments for cancer, diabetes, and infectious diseases, with significant revenue generated from its oncology and vaccine segments. The company also focuses on research and development to innovate new therapies and improve existing ones.

Investment Profile

The stock presents a balanced investment profile, appealing to investors seeking a combination of growth and income through dividends. With a moderate dividend yield and a focus on innovation, it may attract those interested in stable returns while also considering potential capital appreciation.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
3.56 OK
Revenue QoQ — quarter-over-quarter revenue growth
-0.2% ≈
EPS surprise
1.5% in line
20d volatility
2.1% stable
Dividend yield
3.5% moderate last ex-date: 2026-06-15
FMP / FinFeed data updated: 2026-06-09
Reco: Buy Potential: 69 Risk: 40 Updated: 2026-06-11 05:33
How recommendation works
Why AI thinks so:
Strong fundamentals and positive momentum support growth potential.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-06-09 02:45 Hold Buy Stable dividend, moderate growth, cautious market sentiment.
2026-06-01 02:45 Buy Hold Solid dividend yield, but mixed momentum signals.
2026-05-24 02:45 Hold Buy Strong momentum and solid dividend yield support growth.
Analyst forecasts
Date Analyst Action Target Price Then
2026-06-02 10:48 Guggenheim Update — → 140 115.21
2026-05-01 16:03 Morgan Stanley Target Raised 109 → 112 112.47
2026-03-12 11:05 Wells Fargo Target Raised — → 150 116.22
Merck Redwire Eli Lilly

The Pharmaceutical Industry Embraces Space: Drug Development in Low Earth Orbit Gains Momentum

06/09/2026, 12:32 AM growth pharma space Merck Redwire Eli Lilly
The shift of pharmaceutical development to lower Earth orbit represents a significant evolution in the space economy, with the potential to enhance drug formulation and delivery methods. This trend could disrupt traditional pharmaceutical practices and create new investment opportunities as the space economy is projected to exceed $1 trillion by 2040.